It doesn’t have to be that way.
We are very excited to offer semaglutide, It is an FDA approved, weight loss injection! In June 2021, the U.S. FDA approved semaglutide injection (once weekly) for chronic weight management in adults with obesity or overweight with at least one weight-related condition (such as high blood pressure, type 2 diabetes, or high cholesterol etc), for use in addition to a diet and increased physical activity. This under-the-skin injection (subcutaneous) is the first approved drug for chronic weight management in adults with general obesity or overweight since 2014.
Originally used for diabetes and sold under the name Ozempic and Weygovy, a higher dose of the same drug was evaluated for weight loss. The results were dramatic, with the average individual losing 20(+) % of their body weight during the clinic trial.
Semaglutide has shown proven and miraculous results. Peptide optimization therapy are science-backed for gut health, mental focus, anti-aging, and deliver time-tested, noticeable weight loss.
How it works:
Semaglutide works by mimicking a hormone called glucagon-like peptide-1 (GLP-1) that targets areas of the brain that regulate appetite, craving and food intake; it is a powerful appetite suppressant. It also works by increasing the production of insulin and appears to enhance growth of β cells in the pancreas, which are the sites of insulin production. Additionally, it inhibits glucagon, which is a hormone that increases blood sugar. It has
been known to aid not only in weight loss, but helps to lower glucose levels in those who are pre-diabetic (Insulin Resistant) or who have type 2 diabetes
- Delays stomach emptying, leading to a feeling of fullness and smaller meal size.
- Slows intestinal motility
- Lowers blood sugars, in part by reducing the production of sugar in the liver
- Decreases carbohydrate and sugar cravings
You are NOT a good candidate for semaglutide if you have any of the following: diabetic retinopathy, decreased kidney function, pancreatitis, medullary thyroid cancer (or a family history of medullary thyroid carcinoma), or multiple endocrine neoplasia type 2.